The Systemic Lupus Erythematosus (SLE) drug market is currently under-served by non-generic, targeted therapies. Whilst the only Food and Drug Administration (FDA)-approved biologic, Benlysta (belimumab), generated sales of $111m in 2012, there is little evidence that the drug’s performance is significantly superior to other B-cell targeted therapies such as Rituxan (rituximab), which is often used off-license to treat refractory SLE patients. Therapeutics entering the market therefore do not face the staggering level of competition from currently marketed programs as in other markets such as the Rheumatoid Arthritis (RA) market. Emerging market entrants that appear to offer significant therapeutic benefits are likely to cause dramatic changes to the market landscape. A growing understanding of the signaling pathways underlying SLE pathophysiology including, but not limited to, B cells, T cells and intracellular kinases, is translating into a higher number of novel, and more importantly, first-in-class targeted therapeutics entering the developmental pipeline. In particular, a high level of investment in the development of cytokine-blocking strategies is evident, as therapies targeting the interferon pathway are relatively common in the pipeline. Request Sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=145685 . Scope • The report analyzes the market for SLE therapeutics and the pipeline products in that market, with particular emphasis on first-in-class programs. • A brief introduction to SLE, including symptoms, pathophysiology, disease scoring indices and overview of pharmacotherapy • In-depth analysis and literature review on marketed products, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses, based on published clinical trials, as well as a reference table of drugs in terms of safety and efficacy • Overview of how innovation products are contributing to the market for SLE therapeutics • Comprehensive review of the pipeline for first-in-class therapies, which is analyzed on the basis of phase distribution, molecule types and molecular targets, as well as administration routes • The changing molecular target landscape between market and pipeline, and, in particular, focal points of innovation • First-in-class molecular targets, highlighting early-stage programs for which clinical utility has yet to be evaluated, as well as an in-depth literature review on novel molecular targets Complete report is available @ http://www.rnrmarketresearch.com/frontier-pharma-systemic-lupus-erythematosus-identifying-and-commercializing-first-in-class-innovation-market-report.html . Read more on “Frontier Pharma: Systemic Lupus Erythematosus – Identifying and Commercializing First-in-Class Innovation” report below.

1. Frontier Pharma: Systemic Lupus Erythematosus – Identifying and
Commercializing First-in-Class Innovation
by
GBI Research
Explore all reports for “ Autoimmune Drugs ” market
@
http://www.rnrmarketresearch.com/reports/lifesciences/pharmaceuticals/diseasestreatment/autoimmune-drugs .
© RnRMarketResearch.com ;
sales@rnrmarketresearch.com ;
+1 888 391 5441

2. Frontier Pharma: Systemic Lupus Erythematosus – Identifying and
Commercializing First-in-Class Innovation
The Systemic Lupus Erythematosus (SLE) drug market is currently under-served by non-generic,
targeted therapies. Whilst the only Food and Drug Administration (FDA)-approved biologic,
Benlysta (belimumab), generated sales of $111m in 2012, there is little evidence that the drug’s
performance is significantly superior to other B-cell targeted therapies such as Rituxan
(rituximab), which is often used off-license to treat refractory SLE patients. Therapeutics
entering the market therefore do not face the staggering level of competition from currently
marketed programs as in other markets such as the Rheumatoid Arthritis (RA) market.
Emerging market entrants that appear to offer significant therapeutic benefits are likely to
cause dramatic changes to the market landscape.
A growing understanding of the signaling pathways underlying SLE pathophysiology including,
but not limited to, B cells, T cells and intracellular kinases, is translating into a higher number of
novel, and more importantly, first-in-class targeted therapeutics entering the developmental
pipeline. In particular, a high level of investment in the development of cytokine-blocking
strategies is evident, as therapies targeting the interferon pathway are relatively common in the
pipeline.
Inquire for Discount @
http://www.rnrmarketresearch.com/contacts/discount?rname=145685 .
© RnRMarketResearch.com ;
sales@rnrmarketresearch.com ;
+1 888 391 5441

3. Frontier Pharma: Systemic Lupus Erythematosus – Identifying and
Commercializing First-in-Class Innovation
Scope
•The report analyzes the market for SLE therapeutics and the pipeline products in that market, with
particular emphasis on first-in-class programs.
•A brief introduction to SLE, including symptoms, pathophysiology, disease scoring indices and
overview of pharmacotherapy
•In-depth analysis and literature review on marketed products, including analyses of their safety,
efficacy, treatment patterns and strengths/weaknesses, based on published clinical trials, as well as
a reference table of drugs in terms of safety and efficacy
•Overview of how innovation products are contributing to the market for SLE therapeutics
•Comprehensive review of the pipeline for first-in-class therapies, which is analyzed on the basis of
phase distribution, molecule types and molecular targets, as well as administration routes
•The changing molecular target landscape between market and pipeline, and, in particular, focal
points of innovation
•First-in-class molecular targets, highlighting early-stage programs for which clinical utility has yet
to be evaluated, as well as an in-depth literature review on novel molecular targets
Complete Report Available @
http://www.rnrmarketresearch.com/frontier-pharma-systemic-lupus-erythematosusidentifying-and-commercializing-first-in-class-innovation-market-report.html .
© RnRMarketResearch.com ;
sales@rnrmarketresearch.com ;
+1 888 391 5441

4. Frontier Pharma: Systemic Lupus Erythematosus – Identifying and
Commercializing First-in-Class Innovation
Reasons to buy
•The report will assist the business development strategies of companies that wish to develop
novel therapies with improved benefits to existing treatments. It will also be of interest to
companies seeking to expand their pipeline portfolio through licensing agreements and codevelopment deals. Primarily, the report will allow clients to identify and understand market
opportunities and the emerging competitive environment. It will also allow you to •Understand the SLE pipeline and the factors which indicate that it is becoming more innovative
•Understand the overall focal shifts in therapeutic molecular targets for the treatment of SLE
•Understand the distribution of the pipeline programs by phase of development, molecule type
and molecular target
•Identify the list of first-in-class programs that are potentially open to deal-making
opportunities
•Understand the first-in-class developmental programs and gauge the current clinical
effectiveness based on animal models
Buy a copy of report @
http://www.rnrmarketresearch.com/contacts/purchase?rname=145685 .
© RnRMarketResearch.com ;
sales@rnrmarketresearch.com ;
+1 888 391 5441

5. Frontier Pharma: Systemic Lupus Erythematosus – Identifying and
Commercializing First-in-Class Innovation
Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 The Case for Innovation in Systemic Lupus Erythematosus 7
2.2 Growing Opportunities for Biologic Products 7
2.3 Diversification of Molecular Targets 7
2.4 Innovative First-in-Class Product Developments Remain Attractive 8
2.5 Changes in the Clinical and Commercial Environment to be More Favorable to Products
Targeting Niche Patient Populations and Indications 8
2.6 Sustained Innovation 8
3 Systemic Lupus Erythematosus 9
3.1 Disease Overview 9
3.2 Epidemiology 9
Request Sample copy of this report @
http://www.rnrmarketresearch.com/contacts/request-sample?rname=145685 .
© RnRMarketResearch.com ;
sales@rnrmarketresearch.com ;
+1 888 391 5441

6. Frontier Pharma: Systemic Lupus Erythematosus – Identifying and
Commercializing First-in-Class Innovation
For more details contact Mr. Priyank Tiwari: sales@rnrmarketresearch.com /
+18883915441
RnR Market Research
RnRMarketResearch.com, an online repository of market research reports, offers in-depth
analysis of over 5000 market segments. RnR Market Research library has syndicated reports by
leading market research publishers across the globe.
© RnRMarketResearch.com ;
sales@rnrmarketresearch.com ;
+1 888 391 5441